| Literature DB >> 31593516 |
Ashley T Tao1,2, Carrie B Hruska1, Amy L Conners1, Katie N Hunt1, Tiffinee N Swanson1, Thuy D Tran1, Armando Manduca3, Lucas Borges4, Andrew D A Maidment5, David Lake6, Matthew P Johnson7, Rickey E Carter8, Deborah J Rhodes9, Michael K O'Connor1.
Abstract
OBJECTIVE. The purpose of this study was to determine whether application of a proprietary image-processing algorithm would allow a reduction in the necessary administered activity for molecular breast imaging (MBI) examinations. MATERIALS AND METHODS. Images from standard-dose MBI examinations (300 MBq 99mTc-sestamibi) of 50 subjects were analyzed. The images were acquired in dynamic mode and showed at least one breast lesion. Half-dose MBI examinations were simulated by summing one-half of the dynamic frames and were processed with the algorithm under study in both a default and a preferred filter mode. Two breast radiologists independently completed a set of two-alternative forced-choice tasks to compare lesion conspicuity on standard-dose images, half-dose images, and the algorithm-processed half-dose images in both modes. RESULTS. Relative to the standard-dose images, the half-dose images were preferred in 4, the default-filtered half-dose images in 50, and preferred-filtered half-dose images in 76 of 100 readings. Compared with standard-dose images, in terms of lesion conspicuity, the half-dose images were rated better in 2, equivalent in 6, and poorer in 92 of 100 readings. The default-filtered half-dose images were rated better, equivalent, or poorer in 13, 73, and 14 of 100 readings. The preferred-filtered half-dose images were rated as better, equivalent, or poorer in 55, 34, and 11 of 100 readings. CONCLUSION. Compared with that on standard-dose images, lesion conspicuity on images obtained with the algorithm and acquired at one-half the standard dose was equivalent or better without compromise of image quality. The algorithm can also be used to decrease imaging time with a resulting increase in patient comfort and throughput.Entities:
Keywords: breast cancer; cadmium zinc telluride; dose reduction; molecular breast imaging; two-alternative forced choice
Year: 2019 PMID: 31593516 DOI: 10.2214/AJR.19.21582
Source DB: PubMed Journal: AJR Am J Roentgenol ISSN: 0361-803X Impact factor: 3.959